Evidence map›Paper›PMID 33877954›Full record

ArticleHuman vaccines & immunotherapeutics2021

Interrupted time-series analyses of routine vaccination program for elderly pneumonia patients in Japan; an ecological study using aggregated nationwide inpatient data.

Koichi Kobayashi, Taisuke Jo, Wataru Mimura, Maho Suzukawa, Nobuharu Ohshima, Goh Tanaka, Manabu Akazawa, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Koichi KobayashiDepartment of Internal medicine, Yoshikawa Central General Hospital, Saitama, Japan.ORCID 0000-0002-0241-4827
Taisuke JoDepartment of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Wataru MimuraDepartment of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan.ORCID 0000-0001-5704-343X
Maho SuzukawaCenter for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
Nobuharu OhshimaCenter for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.ORCID 0000-0003-1959-1472
Goh TanakaDepartment of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.
Manabu AkazawaDepartment of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan.
Hiroki MatsuiDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Kiyohide FushimiDepartment of Health Policy and Informatics, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Hideo YasunagaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Takahide NagaseDepartment of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.
Hideaki NagaiCenter for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
Tokyo National Hospital · JPThe University of Tokyo · JPMeiji Pharmaceutical University · JPUniversity of Tokyo Health Sciences · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A national routine pneumococcal pneumonia immunization program started in Japan in 2014. It targeted the population aged ≥65 years and used a 23-valent pneumococcal polysaccharide vaccine; PPSV23. However, its effectiveness was not well defined because of the lack of a comprehensive database on the PPSV23 vaccination status of each subject. We used interrupted time-series analyses to assess the changes in the incidence and prognosis of elderly patients hospitalized for pneumonia before and after initiation of the program. First, we estimated the PPSV23 coverage rates in subjects aged ≥65 years based on the number of shipped PPSV23 syringes and the estimated population in each prefecture. The estimated coverage rates reached around 40% in 2014 for the 3 Tohoku prefectures, while those in the other prefectures remained below 20%. After the national routine immunization program started, the estimated coverage rate increased significantly in every prefecture and exceeded 40% in 2017. Next, we aggregated the data extracted from the Japanese Diagnosis Procedure Combination database from April 2011 through February 2017 for hospitalized pneumonia patients aged ≥65 years. The data included data from 655,746 patients, excluding those in the 3 Tohoku prefectures. Interrupted time-series analyses found no change in the incidence of hospitalized pneumonia patients and in-hospital mortality after the vaccination program, but there was a decrease in the in-hospital mortality of pneumonia patients with severe comorbidities defined by the modified Charlson comorbidity index. These results suggest an association between the vaccination program and an improved outcome in hospitalized elderly pneumonia patients with severe comorbidities in Japan.

Indexed as

Pneumococcal InfectionsPneumonia, PneumococcalAgedHumansImmunization ProgramsInpatientsJapanPneumococcal VaccinesVaccinationPneumococcal VaccinesElderlyinpatientJapanese diagnosis procedure combination databasepneumococcal pneumoniapneumococcal polysaccharide vaccine

Identifiers

PMID33877954
PMCPMC8475576
OpenAlexW3155569220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.